TB-500 (Thymosin Beta-4)
A synthetic fragment related to Thymosin Beta-4; not FDA-approved for human use.
What it is
TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring protein involved in cell migration and tissue repair. Like BPC-157 — its constant companion in 'healing stack' marketing — it is not an approved drug in any country.
The evidence base is animal models and laboratory work; thymosin beta-4 itself has seen small human studies in other contexts, but TB-500 as sold online has no published controlled human trials. It also appears on sport anti-doping prohibited lists, which matters for tested athletes.
What researchers have actually studied it for
Wound healing and tissue-repair models in animals; the parent protein has limited early human research in unrelated contexts.
How it works
Thymosin beta-4's day job is binding actin — the protein cells use to move — which makes it central to cell migration into wounds. The TB-500 fragment carries the actin-binding region, and animal models credit it with promoting cell migration, blood-vessel formation and reduced scarring at injury sites.
The molecule itself
A synthetic fragment of thymosin beta-4 centered on the actin-binding domain (commonly the 17-23 region, LKKTETQ) — the piece responsible for cell-migration effects. The full parent is a 43-amino-acid actin-sequestering protein present in nearly every human cell; the fragment is a purpose-cut excerpt.
Where it came from
Thymosin beta-4 came out of 1960s–70s thymus research; its wound-healing thread produced legitimate trials of the full protein (eye injuries, pressure ulcers, cardiac repair) with mixed results that never reached approval. The TB-500 fragment took a different road: veterinary use in racehorses, then the human gray market.
The timeline
1981
Thymosin beta-4 isolated from thymus extracts.
1990s–2000s
Wound-healing and cardiac-repair biology mapped in animals; fragment studies identify the actin-binding core.
2000s
TB-500 emerges in equine racing circles before human gray markets.
2010s
Full-protein human trials (eye, ulcers, cardiac) underperform; fragment never enters trials.
2010s+
Anti-doping sanctions confirm athletic use in humans and horses.
What the research record actually contains
- Animal wound, cardiac and corneal models for thymosin beta-4 and its fragments.
- Small human trials of full-length thymosin beta-4 in unrelated indications — mixed, never approved.
- No published controlled human trials of TB-500 itself.
- Anti-doping positives confirm real-world athletic use, not efficacy.
What could change this assessment
The scientifically live thread belongs to the parent protein and engineered derivatives in academic regenerative research, not the gray-market fragment. Nothing is positioned to generate human data for TB-500 itself.
What's known about risks
No human safety characterization exists for the fragment. The same cell-migration and angiogenesis biology behind the healing hypothesis is biology worth respecting — promoting cell movement is not inherently benign — and gray-market sourcing stacks unverified contents on top.
Where it stands legally
Unapproved everywhere; no compounding pathway; research-chemical channel only. Explicitly prohibited in equine and human sport.
Worth asking a licensed provider
- 1.Does any human evidence connect this fragment to my injury, or only animal models?
- 2.If healing support is the goal, which evidence-backed protocols should we exhaust first?
- 3.Am I subject to any drug testing where this would end my season?
Common claims, corrected
“TB-500 has human trials behind it.”
Reality: The full protein has modest, mixed trials; the fragment sold as TB-500 has none registered anywhere. Marketing merges the files; registries don't.
“Its horse-racing history proves potency.”
Reality: It proves a doping market existed — racing adoption preceded any efficacy evidence and mostly demonstrates the supply chain's origins.
TB-500 (Thymosin Beta-4) FAQ
Are TB-500 and thymosin beta-4 the same thing?
Not exactly — TB-500 is a synthetic fragment of the full protein. Marketing uses the names interchangeably, which lets a fragment borrow the parent molecule's research base.
Is TB-500 banned in sports?
TB-500 appears on anti-doping prohibited lists, and athletes have been sanctioned over it. Tested athletes should treat it as prohibited.
Is there human evidence for TB-500?
No published controlled human trials for the fragment sold online. The healing narrative rests on animal models.
What does actin binding have to do with healing?
Actin is the protein cells use to move; sequestering and releasing it controls migration into wounds. The mechanism is real biology — demonstrated for the parent protein in animals, extrapolated to the fragment by commerce.
Why do TB-500 and BPC-157 keep appearing together?
Forum stack culture paired 'systemic' and 'local' healing narratives, and vendors productized the pairing. The combination has never been studied in any species.